Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changzhou Tianhua Pharmaceutical is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, primarily focusing on the Central Nervous System (CNS) therapeutic area. As a core subsidiary of Jiangsu Nhwa Pharmaceutical, the company operates out of a state-of-the-art facility in the Changzhou Binjiang Chemical Industry Park. Their product portfolio includes high-quality anesthetics, analgesics, and psychotropic drugs that meet international regulatory standards, including US FDA and Chinese GMP. The company provides comprehensive CDMO services, leveraging its expertise in complex chemical synthesis and large-scale production. Changzhou Tianhua plays a critical role in the global supply chain for CNS medications, exporting products to numerous international markets. With a strong emphasis on R&D and quality assurance, the company continues to expand its manufacturing capabilities to support the parent company's growth and external partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changzhou Tianhua.